CYTOKINETICS INC
CYTKNasdaq
$80.18
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +107.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.9M
Enterprise Value
-$516.6M
P/E
—
P/S
0.1
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-5553.6%
Dividend Yield
—
Revenue (TTM)
$105.8M
Net Income (TTM)
-$829.6M
Free Cash Flow (TTM)
-$548.9M
Gross Margin
—
Operating Margin
-605.1%
Net Margin
-784.0%
ROE
100.4%
ROIC
—
Debt / Equity
-0.4
Net Cash
$526.5M
Return 1Y
+106.2%
Company profile
Cytokinetics, Incorporated focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
- CEO
- Robert I. Blum
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 250
- Headquarters
- California
- Website
- cytokinetics.com
Management & directors
- Blum Robert IPresident & CEO
- Malik Fady IbrahamEVP Research & Development
- Callos AndrewEVP, Chief Commercial Officer
- Lee SungEVP, Chief Financial Officer
- Hessekiel JeffreyChief Legal & Admin Officer
Roles derived from SEC Form 4 filings.
Earnings
CYTK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.4M↑ +1125.8%
Diluted EPS-$1.67↑ +22.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$93.9M | -$186.3M | -$324.2M | -$496.2M | -$536.2M | -$612.3M |
| Net income | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Diluted EPS | -$1.97 | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Operating cash flow | $8.9M | -$142.5M | -$299.5M | -$414.3M | -$395.9M | -$510.0M |
| Free cash flow | -$2.1M | -$191.4M | -$310.9M | -$415.7M | -$399.8M | -$534.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -168.3% | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% |
| Net margin | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $249,000.00 | $463,000.00 | $16.9M | $1.6M | $66.8M | $1.9M | $17.8M | $19.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$130.2M | -$140.8M | -$139.0M | -$155.6M | -$111.5M | -$166.8M | -$178.4M | -$183.6M |
| Net income | -$143.3M | -$160.5M | -$150.0M | -$161.4M | -$134.4M | -$306.2M | -$183.0M | -$206.0M |
| Diluted EPS | -$1.31 | -$1.36 | -$1.26 | -$1.36 | -$1.12 | -$2.55 | -$1.51 | -$1.67 |
| Operating cash flow | -$99.3M | -$101.5M | -$65.6M | -$131.6M | -$128.2M | -$107.5M | -$142.7M | -$145.5M |
| Free cash flow | -$101.2M | -$102.2M | -$66.9M | -$137.3M | -$132.4M | -$116.9M | -$148.3M | -$151.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -52277.9% | -30410.6% | -821.4% | -9856.3% | -167.0% | -8613.4% | -1004.6% | -948.7% |
| Net margin | -57557.4% | -34674.9% | -886.3% | -10220.1% | -201.2% | -15815.0% | -1030.9% | -1064.5% |
Company news
Jul 17, 2026
Jul 15, 2026
Jul 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | HENDERSON JOHN T | Award | 272 | $82.62 | $22,472.64 | filing |
| 2026-07-15 | Kaye Edward M. MD | Award | 151 | $82.62 | $12,475.62 | filing |
| 2026-07-15 | Harrington Robert Arthur | Award | 151 | $82.62 | $12,475.62 | filing |
| 2026-07-15 | Daly James M | Award | 151 | $82.62 | $12,475.62 | filing |
| 2026-07-15 | WIERENGA WENDELL | Award | 75 | $82.62 | $6,196.50 | filing |
| 2026-07-15 | Wysenski Nancy | Award | 75 | $82.62 | $6,196.50 | filing |
| 2026-07-13 | Blum Robert I· President & CEO | Sale | 7,490 | $82.02 | $614,329.80 | filing |
| 2026-07-13 | Blum Robert I· President & CEO | Option exercise | 7,490 | $10.60 | $79,394.00 | filing |
| 2026-07-13 | Blum Robert I· President & CEO | Sale | 10 | $82.02 | $820.20 | filing |
| 2026-07-07 | Malik Fady Ibraham· EVP Research & Development | Sale | 3,500 | $86.62 | $303,170.00 | filing |
| 2026-07-07 | Malik Fady Ibraham· EVP Research & Development | Option exercise | 3,500 | $7.80 | $27,300.00 | filing |
| 2026-07-01 | Callos Andrew· EVP, Chief Commercial Officer | Sale | 15,000 | $85.80 | $1.3M | filing |
| 2026-07-01 | Blum Robert I· President & CEO | Sale | 7,500 | $84.92 | $636,900.00 | filing |
| 2026-07-01 | Callos Andrew· EVP, Chief Commercial Officer | Option exercise | 15,000 | $23.26 | $348,900.00 | filing |
| 2026-07-01 | Lee Sung· EVP, Chief Financial Officer | Sale | 1,112 | $87.79 | $97,622.48 | filing |
| 2026-07-01 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 1,112 | $48.51 | $53,943.12 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Sale | 3,134 | $85.00 | $266,390.00 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 1,113 | $48.51 | $53,991.63 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 823 | $44.36 | $36,508.28 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 822 | $44.36 | $36,463.92 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 188 | $44.36 | $8,339.68 | filing |
| 2026-06-29 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 188 | $44.36 | $8,339.68 | filing |
| 2026-06-24 | Lee Sung· EVP, Chief Financial Officer | Sale | 38,730 | $82.30 | $3.2M | filing |
| 2026-06-24 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 23,370 | $48.51 | $1.1M | filing |
| 2026-06-24 | Lee Sung· EVP, Chief Financial Officer | Option exercise | 9,307 | $44.36 | $412,858.52 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.